DURAVYU was non-inferior to on-label aflibercept control (nominal p-value = 0.0096) in an ad hoc analysis excluding a 4% ...
Eyepoint Pharmaceuticals (EYPT) plunged ~70% after its LUGANO Phase 3 trial for Duravyu in wet AMD failed the primary ...
InvestorsHub on MSN
EyePoint DURAVYU phase 3 LUGANO trial misses primary endpoint as secondary data show reduced treatment burden
EyePoint (NASDAQ:EYPT) reported that its Phase 3 LUGANO trial of DURAVYU in wet age-related macular degeneration did not ...
EyePoint, Inc. is rated a Sell, citing unfavorable risk/reward and concerns about commercial relevance against ...
Learn more EyePoint's (EYPT) phase 3 Lugano trial's failure to meet its primary endpoint raises concerns about Duravyu's potential risks in certain patients and whether data from the second pivotal ...
In today's video, I explain the challenging visual approach to Lugano Airport from the pilot's perspective. The footage ...
In Moti Ferder’s lucrative gem-pire, selling fine baubles to A-plus List clients is only half the mission. In the vault at Lugano Diamonds’ headquarters in Newport Beach, California, CEO Moti Ferder ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results